Pre-op eltrombopag reduces need for platelet transfusions

August 23, 2012
Pre-op eltrombopag reduces need for platelet transfusions
For patients with chronic liver disease who require an invasive procedure as part of their routine care, the oral thrombopoietin-receptor agonist eltrombopag reduces the need for platelet transfusions, but also results in an increased incidence of portal-vein thrombosis, according to a study published in the Aug. 23 issue of the New England Journal of Medicine.

(HealthDay)—For patients with chronic liver disease who require an invasive procedure as part of their routine care, the oral thrombopoietin-receptor agonist eltrombopag reduces the need for platelet transfusions, but also results in an increased incidence of portal-vein thrombosis, according to a study published in the Aug. 23 issue of the New England Journal of Medicine.

Nezam H. Afdhal, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues randomly assigned 292 patients with and of less than 50,000 per cubic millimeter to receive either eltrombopag (75 mg daily) or for 14 days before a planned elective , performed within five days of receiving the last dose.

The researchers found that platelet transfusion (before, during, and up to seven days after surgery) was avoided in 104 of 145 patients who received eltrombopag and in 28 of 147 who received placebo (72 versus 19 percent; P < 0.001). There were no significant differences in bleeding episodes of World Health Organization grade 2 or higher, which were reported in 17 percent of the eltrombopag group and 23 percent of the placebo group. Six patients receiving eltrombopag had thrombotic events of the portal venous system, compared with one patient who received placebo, which triggered early termination of the study. Other adverse events were similar in incidence and severity between the groups.

"Eltrombopag reduced the need for platelet transfusions in patients with chronic who were undergoing elective invasive procedures, but it was associated with an increased incidence of portal-vein thrombosis, as compared with placebo," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, which funded the study and manufactures eltrombopag.

Explore further: Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

More information: Full Text (subscription or payment may be required)

Related Stories

Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

July 4, 2012
Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all ...

Drug helps maintain platelet inhibition and anti-clotting levels prior to cardiac surgery

January 17, 2012
Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate ...

Vitreolytic ocriplasmin resolves vitreomacular traction

August 16, 2012
(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according ...

Vandetanib doesn't up survival in non-small-cell lung cancer

March 2, 2012
(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.